Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959706 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Tagworks Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 6
- Study locations
NCT06959706 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Tagworks Pharmaceuticals. The registered enrollment target is 50 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (75% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT06959706, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Tagworks Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.
Conditions Studied
Interventions
- DRUG TGW101
Study Locations (6)
Texas
- University of Texas MD Anderson Cancer Center - Houston
- NEXT Dallas - Irving
- NEXT San Antonio - San Antonio
Arizona
- Honor Health - Scottsdale
Massachusetts
- Massachusetts General Hospital - Boston
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-05-07 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06959706
The ClinicalTrials.gov registry entry for NCT06959706 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (75% lower). The listed sponsor is Tagworks Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which TGW101 is the first listed.
NCT06959706 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Texas, Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06959706 about?
NCT06959706 is a clinical study titled "Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors". The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.
What is the current status of trial NCT06959706?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-05-07. Estimated completion is 2027-09.
What conditions does trial NCT06959706 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06959706?
The interventions under investigation include: TGW101 (DRUG).
Who is sponsoring clinical trial NCT06959706?
This trial is sponsored by Tagworks Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959706 being conducted?
This trial has 6 study locations across Arizona, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.